NRC Health Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-7.8%projected annual EPS growth
Analyst Coverage
1analyst covering
FY Revenue (est.)
$142Mnext fiscal year
FY EPS (est.)
$0.34next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 3 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Total Recurring Contract Value (TRCV) Quarterly152.1MTarget: Continued double-digit year-over-year growth
GAAP Revenue Quarterly34.8MTarget: Sustained positive year-over-year growth trajectory
Operating Margin Quarterly16.0%Target: Expansion back toward historical 20-25% levels
Watch Items
- Landmark Deal Implementation CostsTrigger: Flat adjusted EBITDA margins in Q2 2026Action: Monitor Q3 2026 margin expansion as revenue from the deal begins to be recognized.
- Sales Force Productivity and RetentionTrigger: Slowing of TRCV growth below 10% year-over-yearAction: Evaluate effectiveness of the reconstituted sales force and revamped leadership initiatives.
Research as of 19 Jun 2026